ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

baxdrostat

Also written as “Baxdrostat”, “CIN-107” and “Baxdrostat/dapagliflozin”.

Its studies are mostly in Hypertension · Renal Insufficiency, Chronic · Hyperaldosteronism · Heart Failure · Atherosclerosis, led by 2 companies.

Drug pageBaxdrostat: every studyAll 28 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Sep 6, 202326 company-led studies, 6 open or runningNext primary completion: Dec 10, 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZenecaits history only256 open or runningphase 3since Sep 6, 2023Aug 17, 2020Dec 10, 2026phase 2 · NCT07222917
Hoffmann-La Roche10 open or runningphase 1since Nov 20, 2013Nov 20, 2013none ahead

Also a collaborator on its studies: Tigermed Consulting and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hoffmann-La Roche only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Nov 20, 2013First study: phase 1 study in AtherosclerosisFirst studyNCT01995383 · 88 enrolled · United States
  2. Jul 28, 2021Named baxdrostatINNProposed as its International Nonproprietary Name in WHO's List 125 · before, CIN-107, RO6836191

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

The one study Hoffmann-La Roche leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01995383Atherosclerosis · United States1CompletedJun 201488

How it is read

Names in the registry

  • “Baxdrostat”, 8 entries
  • “CIN-107”, 7 entries
  • “Baxdrostat/dapagliflozin”, 3 entries
  • “baxdrostat”, 3 entries
  • “RO6836191”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.